UBS Maintains Neutral on GoodRx Holdings, Raises Price Target to $3.75

Benzinga Newsdesk www.benzinga.com Positive 71.5%

Neg 0% Neu 0% Pos 71.5%

UBS analyst Kevin Caliendo maintains GoodRx Holdings (NASDAQ:GDRX) with a Neutral and raises the price target from $2.5 to $3.75.